Opinion
Video
Key Points of Emphasis Regarding Biosimilar Integration
Panelists provide final considerations surrounding biosimilar usage and considerations for optimal patient care.
This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.
In final thoughts, Bincy Abraham, MD, MS, said biosimilars are coming and providers should gain confidence through knowledge to educate patients. Hopefully biosimilars reduce societal health care costs and patient costs.
Jamie T. Brogan, APRN, emphasized being confident in biosimilar data, utilizing resources to maintain access, and educating patients and staff.
Alice B. Gottlieb, MD, PhD, said educating prescribers is important for comfort with biosimilars. Payers and pharmacy benefit managers must put patients first and focus on lowering patient costs and improving access.
Vibeke Strand, MD, has confidence in biosimilar efficacy, safety, and immunogenicity. Interchangeability is less important as more biosimilars become available. However, expected cost savings have not reached patients because of system issues. Payers and pharmacy benefit managers must help translate savings to improve patient affordability.
Ryan Haumschild, PharmD, MS, MBA, said closer collaboration between stakeholders is needed to focus on patient interests.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
